

20. An oncolytic adenovirus according to any one of claims 1 to 19, wherein a binding domain in the first BiTE is specific to a tumour antigen, and a binding domain in the second BiTE is specific to a tumour stromal antigen.
21. An oncolytic adenovirus according to any one of the claims 1 to 20, wherein an encoded BiTE comprises a VH domain comprising an amino acid sequence as set forth in SEQ ID NO: 8, or an amino acid sequence that is at least 95% identical thereto and a VL comprising an amino acid sequence as set forth in SEQ ID NO: 9 or a sequence at least 95% identical thereto.
22. An oncolytic adenovirus according to claim 21, wherein the encoded BiTE comprises an scFv comprising an amino acid sequence as set forth in SEQ ID NO: 7 or a sequence at least 95% identical thereto.
23. An oncolytic adenovirus according to any one of the claims 1 to 22, wherein the encoded BiTE comprises a VH domain comprising an amino acid sequence as set forth in SEQ ID NOs: 8, or an amino acid sequence that is at least 95% identical thereto and a VL comprising an amino acid sequence as set forth in SEQ ID NO: 7 or a sequence at least 95% identical thereto.
24. An oncolytic adenovirus according to claim 23, wherein the encoded BiTE comprises an scFv comprising an amino acid sequence as set forth in SEQ ID NO: 7 or a sequence at least 95% identical thereto.
25. An oncolytic adenovirus according to any one of the claims 1 to 24, wherein the encoded BiTE comprises a VH domain comprising an amino acid sequence as set forth in SEQ ID NO: 13, or an amino acid sequence that is at least 95% identical thereto and a VL comprising an amino acid sequence as set forth in SEQ ID NO: 12 or a sequence at least 95% identical thereto.
26. An oncolytic adenovirus according to claim 25, wherein the encoded BiTE comprises an scFv comprising an amino acid sequence as set forth in SEQ ID NO: 11, 74, 75 or a sequence at least 95% identical to any one of the same.
27. An oncolytic adenovirus according to any one of the claims 1 to 26, wherein the encoded BiTE comprises a VH domain comprising an amino acid sequence as set forth in SEQ ID NO: 18, or an amino acid sequence that is at least 95% identical thereto and a VL comprising an amino acid sequence as set forth in SEQ ID NO: 17 or a sequence at least 95% identical thereto.
28. An oncolytic adenovirus according to claim 25, wherein the encoded BiTE comprises an scFv comprising an amino acid sequence as set forth in SEQ ID NOs: 16, 72, 73 or a sequence at least 95% identical to any one of the same.

29. An oncolytic adenovirus according to any one of claims 1 to 28, wherein the adenovirus comprises a sequence shown in SEQ ID NO: 120.
30. An oncolytic adenovirus according to any one of claims 1 to 29, wherein the adenovirus encodes at least one further transgene.
31. An oncolytic adenovirus according to claim 30, wherein the further transgene(s) encodes a cytokine, chemokine and/or an immunomodulator.
32. An oncolytic adenovirus according to claim 31, wherein the further transgene(s) is encoded in position B_γ.
33. An oncolytic adenovirus according to any one of claims 30 to 32, wherein at least one further transgene encodes a cytokine.
34. An oncolytic adenovirus according to claim 33, wherein the cytokine is selected from the group consisting of MIP1 α , IL-1 α , IL-1 β , IL-6, IL-9, IL-12, IL-13, IL-17, IL-18, IL-22, IL-23, IL-24, IL-25, IL-26, IL-27, IL-33, IL-35, IL-2, IL-4, IL-5, IL-7, IL-10, IL-15, IL-21, IL-25, IL-1RA, IFN α , IFN β , IFN γ , TNF α , lymphotoxin α (LTA), Flt3L, GM-CSF and IL-8.
35. An oncolytic adenovirus according to any one of claims 30 to 34, wherein at least one further transgene encodes a chemokine.
36. An oncolytic adenovirus according to claim 35, wherein the chemokine is selected from the group consisting of CCL2, CCL3, CCL5, CCL17, CCL20, CCL22, CXCL9, CXCL10, CXCL11, CXCL13, CXCL12, CCL2, CCL19 and CCL21.
37. A composition comprising an adenovirus according to any one of claims 1 to 36, and a diluent or carrier.
38. A composition according to claim 37, wherein the formulation comprises a second oncolytic virus.
39. A composition according to claim 38, wherein the second oncolytic virus is Ad11 or a derivative thereof.
40. A composition according to claim 39, wherein the second oncolytic virus is Enadenotucirev (EnAd).